Monthly Prescribing Reference

FDA Designates SGK1 Inhibitor Orphan Drug for Long QT Syndrome

LQT-1213 is a first-in-class serum glucocorticoid regulated kinase 1 inhibitor. The Food and Drug Administration (FDA) has granted Orphan Drug designation to LQT-1213, a first-in-class serum ...
WTNH

Thryv Therapeutics Granted FDA Orphan Drug Designation for LQT-1213 in Long QT Syndrome Treatment

MONTREAL, Oct. 1, 2024 /PRNewswire/ - Thryv Therapeutics, a clinical stage biotech company dedicated to developing treatments for rare and life-threatening cardiovascular indications, today announced ...
Healio

In long QT syndrome, vigorous exercise appears OK regardless of age, sex, genotype

Please provide your email address to receive an email when new articles are posted on . In long QT syndrome, patients doing vigorous exercise did not have more events than those doing nonvigorous ...
News Medical

Innovative genomic approach identifies rare Long QT syndrome carriers

An innovative analysis of shared segments within the genome - an indication of distant "relatedness" - has identified undiagnosed cases of Long QT syndrome, a rare disorder that can lead to abnormal ...